Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Analog Devices to buy Alif Semiconductor for USD 1.35 billion cash

Analog Devices to buy Alif Semiconductor for USD 1.35 billion cash

ReutersReuters2026/09/09 12:03
  • Analog Devices to buy Alif Semiconductor for USD 1.35 billion in cash.
  • Deal adds Alif’s AI-native microcontrollers and fusion processors to support edge inference and real-time sensor fusion.
  • Agreement includes up to USD 200 million in contingent consideration.
  • Closing targeted before the end of calendar 2026, subject to customary closing conditions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Analog Devices Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE43376) on September 09, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Survival Nearly Doubles! BioNTech (BNTX.US) Lung Cancer Candidate Drug PRESERVE-003 Achieves Success in Late-Stage Trial, Providing Critical Support for Oncology Transformation

BioNTech (BNTX.US) announced on Monday that a late-stage clinical trial demonstrated its candidate drug gotistobart provided a clinically meaningful overall survival benefit compared to standard therapy in a specific type of lung cancer.

智通财经2026/09/14 10:46
Survival Nearly Doubles! BioNTech (BNTX.US) Lung Cancer Candidate Drug PRESERVE-003 Achieves Success in Late-Stage Trial, Providing Critical Support for Oncology Transformation